Publication date: Available online 2 March 2020Source: Allergology InternationalAuthor(s): Hiroyuki Nagase, Shigeharu Ueki, Shigeharu Fujieda
Tue Mar 03, 2020 13:06
Abstract New therapeutic options for severe asthma have recently emerged, mostly in the form of monoclonal antibodies (“biologicals”) targeting relevant inflammatory pathways. Currently available agents target different aspects of ‘Type 2’ immunity and their indications often include overlapping patient groups. We present a round table discussion that took place during the Annual Meeting of the Respiratory Effectiveness Group (REG), on the reasoning behind the use of different add‐on medications...
03:39
Abstract Regulatory T (Treg) cells potentially suppress the deleterious activities of effector T cells and maintain a state of tolerance against antigens in the airway mucosa. A decrease in the number and function of Treg cells is observed in T helper 2 (Th2)‐biased allergic airway diseases. However, adoptive transfer of naturally occurring Treg (tTreg) cells or peripherally derived Treg (pTreg) cells in asthmatic mouse models did not yield satisfactory results in any previous studies. Here, we...
03:39
Anaphylaxis is a serious potentially life-threatening allergic reaction. Most episodes of anaphylaxis are triggered through an immunologic mechanism involving immunoglobulin E (IgE) which leads to mast cell and basophil activation and the subsequent release of inflammatory mediators1. Anaphylaxis typically involves the cutaneous, respiratory, cardiovascular, and gastrointestinal systems, target organs all heavily populated with mast cells2. Death due to anaphylaxis usually occurs as a result of respiratory...
Tue Mar 03, 2020 02:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου